Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 17/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689479 | 0.78 | CDC7 (0.61) | CDC7CSNK1A1CSNK1DCLK2CSNK1G1 | |
| SCHEMBL7486143 | 0.74 | LRRK2 (0.39) | CDC7 | |
| SCHEMBL7690471 | 0.73 | CDC7 (0.66) | CDC7CSNK1A1CSNK1DCLK2CSNK1G1 | |
| SCHEMBL7684925 | 0.71 | BUB1 (0.65) | BUB1 | |
| SCHEMBL6809044 | 0.70 | KMT2A (0.38) | CDC7BUB1 | |
| SCHEMBL4771586 | 0.68 | CDC7 (1.00) | CDC7CSNK1A1CSNK1DCLK2CSNK1G1 | |
| SCHEMBL7689906 | 0.67 | CDC7 (0.57) | CDC7CSNK1A1CSNK1DCLK2CSNK1G1 | |
| Hydrochloric Acid SCHEMBL4772983 | 0.67 | CDC7 (0.97) | CDC7CSNK1A1CSNK1DCLK2CSNK1G1 | |
| SCHEMBL7680905 | 0.67 | BUB1 (0.62) | CDC7BUB1 | |
| SCHEMBL17847544 | 0.64 | RIPK3 (0.58) | CDC7BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | claimed |
| EP-0912548-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002430-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1998-01-22 | — | — | WO | claimed |
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| EP-0912548-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002430-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | CDC7 2195/4885CSNK1A1 2321/4885CSNK1D 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.